Clinical trials: Helicobacter Pylori Eradication
Gastric Cancer
Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study
In this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or…
- Trial name
- NCT03978481
- Testing
- Helicobacter pylori eradication (combination therapy)
- Where
- South Korea
- Volunteers
- 3,700 people
- Sponsor
- Seoul National University Bundang Hospital
Mucosa-Associated Lymphoid Tissue Lymphoma
Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma
Gastric low-grade mucosa-associated lymphoid tissue lymphoma (MALToma) is associated with Helicobacter pylori (HP) infection, and around 70% of these tumors can be cured by HP eradication therapy (HPE).
- Trial name
- NCT02987127
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
H.Pylori Gastrointestinal Disease
Eradication Rate Between 1- and 2-Week Helicobacter Pylori Eradication Therapy
It is recommended as the first line treatment regimen to eradicate Helicobacter pylori (HP), 7 or 14 days treatment of proton pump inhibitor (PPI) based triple therapy consisting of one PPI and two antibiotics, clarithromycin and…
- Trial name
- NCT02487511
- Testing
- Duration of HP therapy
- Where
- South Korea
- Volunteers
- 387 people
- Sponsor
- St.Paul's Hospital, Korea
Helicobacter Pylori Infection
Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection
This study intends to collect the clinical data of patients with Helicobacter pylori infection, and to observe and count the high-dose double therapy and the traditional quadruple / triple therapy ( i.e., esomeprazole +…
- Trial name
- NCT06250634
- Testing
- esomeprazole + amoxicillin, esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent, Vonoprazan + amoxicillin
- Where
- China
- Volunteers
- 806 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Helicobacter Pylori Infection
Molecular Detection of Antibiotic Resistance and H Pylori Eradication
H pylori eradication failure with recommended triple therapy is mainly related to antibiotic resistance. However,IN VITRO culture of H pylori is uneasy and is not performed in routine practice.
- Trial name
- HELICOSTIC (NCT01168063)
- Testing
- Molecular detection of antibiotic resistance, standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)
- Where
- France
- Volunteers
- 1,386 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
H.Pylori Infection, H.Pylori Gastrointestinal Disease
Concomitant Versus Hybrid Regimen for H. Pylori Eradication
10 day concomitant versus 14 day hybrid regimen as first line H. pylori eradication treatment in a high clarithromycin resistance area. A multicenter, randomized, equivalence trial.
- Conditions
- H.Pylori Infection, H.Pylori Gastrointestinal Disease, H. Pylori Associated Phlegmonous Gastritis
- Trial name
- NCT03592069
- Testing
- 10 day concomitant regimen, 14 day hybrid regimen
- Where
- Greece
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Alexandra Hospital, Athens, Greece
H. Pylori Infection
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
All patients who presented with epigastric pain and dyspeptic symptoms will undergo endoscopic gastric biopsies. The patients will be subjected to: Full history taking, clinical examination, liver function tests, renal function…
- Trial name
- NCT06050824
- Testing
- Comparing Load and Concomitant therapy
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Helwan University
Helicobacter Pylori Infection, Resistant Infection
One Sequencing Find All for Helicobacter Pylori Infection
The aim of this study is to Identify antibiotic resistance gene mutations in Helicobacter pylori (HP) and genetic diversity of drug metabolism for antibiotics and proton pump inhibitors (PPIs) in patients with HP infection using…
- Trial name
- NCT03837990
- Testing
- Helicobacter Pylori eradication therapy
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Helicobacter Pylori Infection
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical efficiency and safety of Banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the…
- Trial name
- NCT06340724
- Testing
- Vonoprazan, Amoxicillin, Banxiaxiexin decoction
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection, Dyspepsia
Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri
Helicobacter pylori colonizes approximately to 50% of the world-wide population. There is an exigency to find routes alternating to control the infection with an ample perspective but without the complications of induction of…
- Trial name
- NCT01028690
- Testing
- Lactobacillus reuteri
- Where
- Mexico
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centro Regional para el Estudio de las Enfermedades Digestivas
Helicobacter Pylori Infection
Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection
Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H.
- Trial name
- NCT01643785
- Testing
- Second-line quadruple therapy with endonase
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Helicobacter Pylori Infection
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the…
- Trial name
- NCT03722433
- Testing
- Vigiis 101-LAB and sequential therapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Tailored Therapy for Helicobacter Pylori in Children
This study is designed to compare the eradication rates，safety and compliance of tailored therapy to those of standard triple therapy in children with H. pylori infection.
- Trial name
- NCT02635191
- Testing
- Tailored Group, Standard group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Children's Hospital
Helicobacter Pylori Infection
Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori (H. pylori). A total of 162 patients with H.
- Trial name
- NCT03108287
- Testing
- RAK therapy, RBAK therapy
- Volunteers
- 162 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Helicobacter Pylori Infection, Family History of Stomach Cancer
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
In this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple therapy in comparison with that of 7-day PPI-based standard triple as 1st line treatment for H. pylori.
- Trial name
- NCT02557932
- Testing
- Standard triple therapy, Bismuth quadruple therapy
- Where
- South Korea
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Helicobacter Pylori Infection
The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics.
- Trial name
- NCT05189444
- Testing
- Vonoprazan, Amoxicillin, Esomeprazole
- Where
- China
- Volunteers
- 672 people
- Sponsor
- Huazhong University of Science and Technology
Helicobacter Pylori Infection
Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication
Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical efficiency and safety of Zuojin Wan combined with vonoprazan and high-dose amoxicillin dual therapy in the treatment of…
- Trial name
- NCT06901375
- Testing
- Vonoprazan, Amoxicillin, Zuojin Wan
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based regimens as primary therapies in eradicating H. pylori.
- Trial name
- NCT03716622
- Testing
- Furazolidone, Clarithromycin
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
Tegoprazan-containing Sequential for H. Pylori
As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential…
- Trial name
- NCT06382493
- Testing
- Tegoprazan-containing sequential H. pylori eradication therapy, Esomeprazole-containing sequential H. pylori eradication therapy
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.
- Trial name
- NCT05493644
- Testing
- Remedial treatment within 3 months, Remedial treatment within 3 to 6 months, Remedial treatment within 6 to 12 months
- Volunteers
- 660 people
- Sponsor
- Shandong University